Top 10 Stocks to Buy According to 12 West Capital Management

5. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Number of Hedge Fund Holders as of Q4: 25

12 West Capital Management’s Equity Stake: $63.17 Million 

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) specializes in providing essential products that support the development of drug therapies, novel vaccines, and diagnostics, while also advancing research on human diseases through proprietary technologies. Its client portfolio includes leading companies such as TriLink Biotechnologies, Glen Research, Cygnus Technologies, and Vector Laboratories, with expertise in biologics safety testing, nucleic acid production, and protein detection. Based in San Diego, California, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) plays a critical role in the life sciences sector.

On March 18, 2025, the company released its financial results for Q4 2024 and the full year. CEO Trey Martin acknowledged that while the fourth-quarter revenue was within the projected range, challenges arose due to economic uncertainties and shifting customer spending priorities. However, he highlighted the company’s progress, including facility expansions, new product launches, and strategic acquisitions, which have reinforced Maravai’s long-term growth strategy. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) remains committed to leveraging its unique technologies to support clients from early-stage discovery through commercialization.

The company’s fourth-quarter revenue totaled $56.6 million, marking a 23.7% year-over-year decline. Nucleic Acid Production revenue dropped 28.8% to $41.9 million, primarily due to the absence of large GMP orders seen in 2023 and weaker demand for research-related products. Biologics Safety Testing revenue fell 4.3% to $14.7 million, reflecting reduced bioprocessing market demand. Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) reported a net loss of $46.1 million and an adjusted EBITDA loss of $1.1 million, compared to a net loss of $110 million and adjusted EBITDA of $20.5 million in Q4 2023.

For the full year 2024, revenue declined 10.3% to $259.2 million. Nucleic Acid Production revenue was $196.3 million, down 12.6% due to decreased demand for research and discovery products. Biologics Safety Testing revenue slipped 2.1% to $62.8 million, mainly attributed to weaker demand in China’s bioprocessing sector. The company posted a net loss of $259.6 million and adjusted EBITDA of $35.9 million, compared to a net loss of $138.4 million and adjusted EBITDA of $65.3 million in 2023. Despite these financial headwinds, Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) continues to focus on strategic initiatives aimed at driving future growth.